Home > Drug Safety & Recalls > FDA Side Effect Updates > FDA Side Effect Update: NSAIDs and Life-Threatening Reactions

FDA Side Effect Update: NSAIDs and Life-Threatening Reactions

Safety updates sourced directly from the FDA's Drug Safety Database, presented in clear and accessible language

Katie Rowley

December 11, 2024

0 Comments

republish

Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your NSAIDs medications.

How to Read This Report

This report is prepared using the most recent information posted in the SrLC database. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.

Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.

Side Effect Update for Prescription NSAIDs

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used pain medicines. Available both over-the-counter and in prescription-only formulations, NSAID medications are used to treat fever, muscle pain, arthritis pain, headaches, menstrual cramps, pain caused by injuries or surgery, and more.

NSAID medications may be taken as capsules, tablets, liquid, topical creams, and by I.V. or injection in a hospital setting.

In the fourth quarter of 2022, the FDA reported that it had received a number of NSAID-related adverse events reports for a serious skin reaction called “generalized bullous fixed drug eruption” and that it would “evaluate the need for regulatory action.” Fixed drug eruption is a serious skin rash or blistering reaction to a drug that usually occurs in the same location each time the person uses the medication.

In July 2024, the FDA began to notify NSAID manufacturers that labels should be updated to include warnings about fixed drug eruptions. The required updates only include prescription NSAIDs, not over-the-counter versions like Advil, Aleve, and Motrin. Over-the-counter NSAID labels include a general warning about potential skin reactions, but do not specify the risk of “fixed drug eruptions.”

Starting on November 21, 2024, more than 50 safety updates for prescription NSAIDs were filed with the FDA. Here are descriptions of the updates for some of the more commonly prescribed medications in the category. Please check the SRLC database to search for additional NSAID drugs.

Arthrotec (active ingredient: diclofenac sodium; misoprostol)

Initial FDA Approval: 1997

Side Effect Update Date: November 21, 2024

Medication Description: Treats osteoarthritis and rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers.

Updated Side Effects/Safety Information: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.

FDA Safety Announcement: Arthrotec FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Cambia (active ingredient: diclofenac potassium) powder

Initial FDA Approval: 1998

Side Effect Update Date: November 21, 2024

Medication Description: Treats attacks of migraine headaches in adults.

Essential Extras: Administered from a one-dose packet with powder that is mixed with water.

FDA Safety Announcement: Cambia FDA Safety Label Change and Revised drug label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Celebrex (active ingredient: celexocib)

Initial FDA Approval: 1998

Side Effect Update Date: November 21, 2024

Medication Description: Treats osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA) ankylosing spondylitis, acute pain, menstrual cramps.

FDA Safety Announcement: Celebrex FDA Safety Label Change and Revised drug label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Daypro (active ingredient: oxaprozin) caplets

Initial FDA Approval: 1992

NSAIDs Side Effect Update Date: November 21, 2024

Medication Description: Treats osteoarthritis (OA) and rheumatoid arthritis (RA)

FDA Safety Announcement: Daypro FDA Safety Label Change and Revised drug label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Duexis (active ingredient: famotidine; ibuprofen)

Initial FDA Approval: 2011

Side Effect Update Date: November 21, 2024

Medication Description: Treats osteoarthritis (OA) and rheumatoid arthritis (RA) while decreasing the risk of developing an ulcer from ibuprofen use.

FDA Safety Announcement: Duexis FDA Safety Label Change and Revised drug label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Feldene (active ingredient: piroxicam)

Initial FDA Approval: 1982

Side Effect Update Date: November 21, 2024

Medication Description: Treats osteoarthritis (OA) and rheumatoid arthritis (RA)

Updated NSAIDs Side Effects/Safety Information: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.

FDA Safety Announcement: Feldene FDA Safety Label Change and Revised drug label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Indocin (indomethacin) oral suspension and indomethacin (indomethacin) (various formulations)

Initial FDA Approval: 1985 (oral suspension formulation); 1965 (capsules)

Side Effect Update Date: November 21, 2024

Medication Description: Treats moderate to severe rheumatoid arthritis (RA) including acute flares; ankylosing spondylitis; osteoarthritis; acute painful shoulder; gouty arthritis

FDA Safety Announcement: Indocin Safety Label Change and Revised Drug Label

Indomethacin FDA Safety Label Change and Revised drug label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Meloxicam (active ingredient: meloxicam) oral suspension

Initial FDA Approval: 2004

Side Effect Update Date: November 21, 2024

Medication Description: Treats osteoarthritis (OA), rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)

FDA Safety Announcement: Meloxicam FDA Safety Label Change and Revised Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Naprosyn (naproxen) tablets and EC-NAPROSYN (naproxen) delayed release tablets, and ANAPROX DS (naproxen sodium) tablets

Initial FDA Approval:1976

Side Effect Update Date: November 21, 2024

NSAIDs Description: Treats moderate to severe rheumatoid arthritis (RA); ankylosing spondylitis; osteoarthritis; bursitis; gout; menstrual cramps; pain management.

Updated NSAIDs Side Effects/Safety Information: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.

FDA Safety Announcement: Naprosyn FDA Safety Label Change and Revised Drug Label (covers all 3 versions of naproxen)
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Zipsor (diclofenac potassium) tablets

Initial FDA Approval: 1988

Side Effect Update Date: November 21, 2024

NSAIDs Description: Treats mild to moderate acute (not chronic) pain in adults and children age 12 and up.

FDA Safety Announcement: Zipsor FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.

Essential Safety Extras for All NSAIDs Prescription Drugs:

All include a boxed warning for “serious cardiovascular and gastrointestinal events.”

FDA NSAIDs Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes

In October 2020, the FDA released a safety communication stating that use of NSAIDs around 20 weeks or later in pregnancy may cause rare but serious kidney problems in an unborn baby. This can lead to low levels of amniotic fluid surrounding the baby and possible complications.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication – Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later | FDA

FDA safety information page on NSAIDs: Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | FDA

Want to Share Your Story?

If you’ve experienced side effects or medication issues related to this topic, we want to hear from you.

Submit Your Story

republish this story

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

FDA SIDE EFFECTS UPDATE: Antidepressants, Stimulants May Interfere With Parkinson’s Test

May 14, 2026

FDA SIDE EFFECTS UPDATE: Seizure and Vitamin Deficiency Risk for Parkinson’s Drugs

April 20, 2026

FDA SIDE EFFECTS UPDATE: Children’s Zyrtec Linked to Withdrawal Itching, Finasteride Tied to Suicidal Thoughts, and More

DONATE:

Help fund our fight for improved medication safety and transparency by supporting our independent journalism.

Give Now

We seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.

Our Mission

MedShadow Foundation

Our Founder

Republish This Story for Free

Creative Commons License (CC BY-NC-ND 4.0)

MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.

We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.

As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:

You May Republish Our Articles for Free If:

1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:

This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.

2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.

3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.

4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.

You May Not:

Use our content to promote a product, service, or political candidate
Republish only part of an article or create derivative works without permission
Add affiliate links, advertising overlays, or lead generators
Translate the article without written permission

Contact Us

If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org

We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.

Article HTML

<!-- wp:paragraph -->
<p>Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your NSAIDs medications.</p>
<!-- /wp:paragraph --><!-- wp:heading -->
<h2 class="wp-block-heading" id="h.bfs426nnx0aa">How to Read This Report</h2>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>This report is prepared using the most recent information posted in the <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm" target="_blank" rel="noreferrer noopener">SrLC database</a>. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.</p>
<!-- /wp:paragraph --><!-- wp:heading -->
<h2 class="wp-block-heading" id="h.zd2zum7l65mt">Side Effect Update for Prescription NSAIDs</h2>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><a href="https://www.ncbi.nlm.nih.gov/books/NBK547742/" target="_blank" rel="noreferrer noopener">Nonsteroidal anti-inflammatory drugs (NSAIDs)</a> are among the most commonly used pain medicines. Available both over-the-counter and in prescription-only formulations, NSAID medications are used to treat fever, muscle pain, arthritis pain, headaches, menstrual cramps, pain caused by injuries or surgery, and more.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>NSAID<a href="https://medshadow.org/nsaids/" target="_blank" rel="noreferrer noopener"> medications</a> may be taken as capsules, tablets, liquid, topical creams, and by I.V. or injection in a hospital setting.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>In the fourth quarter of 2022, the <a href="https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/october-december-2022-potential-signals-serious-risksnew-safety-information-identified-fda-adverse" target="_blank" rel="noreferrer noopener">FDA reported</a> that it had received a number of NSAID-related adverse events reports for a serious skin reaction called “generalized bullous fixed drug eruption” and that it would “evaluate the need for regulatory action.” <a href="https://medlineplus.gov/ency/imagepages/2421.htm" target="_blank" rel="noreferrer noopener">Fixed drug eruption</a> is a serious skin rash or blistering reaction to a drug that usually occurs in the same location each time the person uses the medication.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>In July 2024, the FDA <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/018147Orig1s053ltr.pdf" target="_blank" rel="noreferrer noopener">began to notify</a> NSAID manufacturers that labels should be updated to include warnings about fixed drug eruptions. The required updates only include prescription NSAIDs, not over-the-counter versions like Advil, Aleve, and Motrin. Over-the-counter NSAID labels include a general warning about potential skin reactions, but do not specify the risk of “fixed drug eruptions.”</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Starting on November 21, 2024, more than 50 safety updates for prescription NSAIDs were filed with the FDA. Here are descriptions of the updates for some of the more commonly prescribed medications in the category. Please check the <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=184" target="_blank" rel="noreferrer noopener">SRLC database</a> to search for additional NSAID drugs.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Arthrotec (active ingredient: diclofenac sodium; misoprostol)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1997</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats osteoarthritis and rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=150" target="_blank" rel="noreferrer noopener">Arthrotec FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020607s043lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Cambia (active ingredient: diclofenac potassium) powder</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1998</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats attacks of migraine headaches in adults.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: Administered from a one-dose packet with powder that is mixed with water.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=152" target="_blank" rel="noreferrer noopener">Cambia FDA Safety</a> Label Change  and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022165s016lbl.pdf" target="_blank" rel="noreferrer noopener">Revised drug label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Celebrex (active ingredient: celexocib)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1998</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA) ankylosing spondylitis, acute pain, menstrual cramps.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=154" target="_blank" rel="noreferrer noopener">Celebrex FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020998s058lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised drug label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Daypro (active ingredient: oxaprozin) caplets</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1992</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>NSAIDs  Side Effect Update Date</strong>: November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats osteoarthritis (OA) and rheumatoid arthritis (RA)</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>:<a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=155" target="_blank" rel="noreferrer noopener"> Daypro FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018841s036lbl.pdf" target="_blank" rel="noreferrer noopener">Revised drug label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Duexis (active ingredient: famotidine; ibuprofen)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2011</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats osteoarthritis (OA) and rheumatoid arthritis (RA) while decreasing the risk of developing an ulcer from ibuprofen use.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>:<a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=155" target="_blank" rel="noreferrer noopener"> Duexis FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022519s014lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised drug label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Feldene (active ingredient: piroxicam)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1982</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats osteoarthritis (OA) and rheumatoid arthritis (RA)</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated NSAIDs Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=177" target="_blank" rel="noreferrer noopener">Feldene FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018147s053lbl.pdf" target="_blank" rel="noreferrer noopener">Revised drug label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Indocin (indomethacin) oral suspension and indomethacin (indomethacin) (various formulations)</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1985 (oral suspension formulation); 1965 (capsules)</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description:</strong> Treats moderate to severe rheumatoid arthritis (RA) including acute flares; ankylosing spondylitis; osteoarthritis; acute painful shoulder; gouty arthritis</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=184" target="_blank" rel="noreferrer noopener">Indocin Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018841s036lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=189" target="_blank" rel="noreferrer noopener">Indomethacin FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018851s029lbl.pdf" target="_blank" rel="noreferrer noopener">Revised drug label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Meloxicam (active ingredient: meloxicam) oral suspension</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 2004</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: Treats osteoarthritis (OA), rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=downloadDetails.page&DrugNameID=3055" target="_blank" rel="noreferrer noopener">Meloxicam FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021530s020lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Naprosyn (naproxen) tablets and EC-NAPROSYN (naproxen) delayed release tablets, and ANAPROX DS (naproxen sodium) tablets</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>:1976</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>NSAIDs Description</strong>: Treats moderate to severe rheumatoid arthritis (RA); ankylosing spondylitis; osteoarthritis; bursitis; gout; menstrual cramps; pain management.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated NSAIDs  Side Effects/Safety Information:</strong> Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=201" target="_blank" rel="noreferrer noopener">Naprosyn FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/017581s117,018164s067,020067s026lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label</a> (covers all 3 versions of naproxen)<br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Zipsor (diclofenac potassium) tablets</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1988</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: November 21, 2024</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>NSAIDs Description</strong>: Treats mild to moderate acute (not chronic) pain in adults and children age 12 and up.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effects/Safety Information</strong>: Warns of the risk of a serious skin reaction called fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=214" target="_blank" rel="noreferrer noopener">Zipsor FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022202s016lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label</a><br>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading">Essential Safety Extras for All NSAIDs Prescription Drugs:</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>All include a boxed warning for “serious cardiovascular and gastrointestinal events.”</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA NSAIDs </strong><strong>Safety Communication</strong>: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>In October 2020, the FDA released a safety communication stating that use of NSAIDs around 20 weeks or later in pregnancy may cause rare but serious kidney problems in an unborn baby. This can lead to low levels of amniotic fluid surrounding the baby and possible complications.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><a href="https://www.fda.gov/safety/medical-product-safety-information/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communication-avoid-use-nsaids-pregnancy-20" target="_blank" rel="noreferrer noopener">Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication – Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later | FDA</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA safety information page on NSAIDs</strong>: Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | FDA</p>
<!-- /wp:paragraph -->

FDA Side Effect Update: NSAIDs and Life-Threatening Reactions

How to Read This Report

Side Effect Update for Prescription NSAIDs

Arthrotec (active ingredient: diclofenac sodium; misoprostol)